Evidence map›Paper›PMID 30428571›Full record

ArticleCancers2018

Focal Adhesion Genes Refine the Intermediate-Risk Cytogenetic Classification of Acute Myeloid Leukemia.

Victor Pallarès, Montserrat Hoyos, M Carmen Chillón, Eva Barragán, M Isabel Prieto Conde, Marta Llop, Aïda Falgàs, María Virtudes Céspedes, Pau Montesinos, Josep F Nomdedeu and 6 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

Victor PallarèsBiomedical Research Institute Sant Pau (IIB Sant Pau), Hospital de la Santa Creu i Sant Pau, Sant Antoni Maria Claret 167, Pavelló 11, 2n pis, 08025 Barcelona, Spain. mpallaresl@santpau.cat.ORCID 0000-0002-9851-0345
Montserrat HoyosBiomedical Research Institute Sant Pau (IIB Sant Pau), Hospital de la Santa Creu i Sant Pau, Sant Antoni Maria Claret 167, Pavelló 11, 2n pis, 08025 Barcelona, Spain. mhoyos@santpau.cat.
M Carmen ChillónServicio de Hematología, IBSAL-Hospital Universitario, Centro de Investigación del Cáncer (CIC)-IBMCC, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Universidad de Salamanca, 37007 Salamanca, Spain. chillon@usal.es.ORCID 0000-0003-1624-6059
Eva BarragánHematology Department, Hospital Universitari i Politècnic La Fe, Department of Medicine, University of Valencia, and Centro de Investigación Biomédica en Red de Cáncer, Instituto Carlos III, 46026 Valencia, Spain. barragan_eva@gva.es.
M Isabel Prieto CondeServicio de Hematología, IBSAL-Hospital Universitario, Centro de Investigación del Cáncer (CIC)-IBMCC, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Universidad de Salamanca, 37007 Salamanca, Spain. i.prietoconde@usal.es.
Marta LlopHematology Department, Hospital Universitari i Politècnic La Fe, Department of Medicine, University of Valencia, and Centro de Investigación Biomédica en Red de Cáncer, Instituto Carlos III, 46026 Valencia, Spain. llop_mar@gva.es.
Aïda FalgàsBiomedical Research Institute Sant Pau (IIB Sant Pau), Hospital de la Santa Creu i Sant Pau, Sant Antoni Maria Claret 167, Pavelló 11, 2n pis, 08025 Barcelona, Spain. AFalgas@santpau.cat.
María Virtudes CéspedesBiomedical Research Institute Sant Pau (IIB Sant Pau), Hospital de la Santa Creu i Sant Pau, Sant Antoni Maria Claret 167, Pavelló 11, 2n pis, 08025 Barcelona, Spain. mcespedes@santpau.cat.
Pau MontesinosHematology Department, Hospital Universitari i Politècnic La Fe, Department of Medicine, University of Valencia, and Centro de Investigación Biomédica en Red de Cáncer, Instituto Carlos III, 46026 Valencia, Spain. montesinos_pau@gva.es.
Josep F NomdedeuDepartment of Hematology, Hospital de la Santa Creu i Sant Pau, Mas Casanovas nº 90, 08041 Barcelona, Spain. jnomdedeu@santpau.cat.
Salut BrunetDepartment of Hematology, Hospital de la Santa Creu i Sant Pau, Mas Casanovas nº 90, 08041 Barcelona, Spain. sbrunet@santpau.cat.
Miguel Ángel SanzHematology Department, Hospital Universitari i Politècnic La Fe, Department of Medicine, University of Valencia, and Centro de Investigación Biomédica en Red de Cáncer, Instituto Carlos III, 46026 Valencia, Spain. msanz@uv.es.
Marcos González-DíazServicio de Hematología, IBSAL-Hospital Universitario, Centro de Investigación del Cáncer (CIC)-IBMCC, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Universidad de Salamanca, 37007 Salamanca, Spain. margondi@usal.es.
Jorge SierraDepartment of Hematology, Hospital de la Santa Creu i Sant Pau, Mas Casanovas nº 90, 08041 Barcelona, Spain. jsierra@santpau.cat.
Ramon ManguesBiomedical Research Institute Sant Pau (IIB Sant Pau), Hospital de la Santa Creu i Sant Pau, Sant Antoni Maria Claret 167, Pavelló 11, 2n pis, 08025 Barcelona, Spain. rmangues@santpau.cat.ORCID 0000-0003-2661-9525
Isolda CasanovaBiomedical Research Institute Sant Pau (IIB Sant Pau), Hospital de la Santa Creu i Sant Pau, Sant Antoni Maria Claret 167, Pavelló 11, 2n pis, 08025 Barcelona, Spain. icasanova@santpau.cat.
Hospital de Sant Pau · ESUniversitat de València · ESUniversidad de Salamanca · ESUniversitat Autònoma de Barcelona · ES

Funding

Agència de Gestió d'Ajuts Universitaris i de Recerca 2014PROD0005Agència de Gestió d'Ajuts Universitaris i de Recerca 2014-SGR-1281Agència de Gestió d'Ajuts Universitaris i de Recerca 2017 FI_B 00680Agència de Gestió d'Ajuts Universitaris i de Recerca 2017-SGR-865Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina CBV6/01/1031Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina Nanomets3CIBERONC CB16/12/00284Fundació la Marató de TV3 100830/31/32Fundació la Marató de TV3 416/C/2013-2030Fundación Cellex GrantFundación Científica Asociación Española Contra el Cáncer GrantFundación Española de Hematología y Hemoterapia GrantFundación Josep Carreras Contra la Leucemia P/AG 2017Generalitat de Catalunya (PERIS) SLT002/16/00433Instituto de Salud Carlos III CD13/00074Instituto de Salud Carlos III ISCIII-PS13/1640Instituto de Salud Carlos III PI14/00450Instituto de Salud Carlos III PI15/00378Instituto de Salud Carlos III PI16/0665Instituto de Salud Carlos III PI17/01246Instituto de Salud Carlos III PIE13/00046Instituto de Salud Carlos III PIE15/00028Instituto de Salud Carlos III RD12/0036/0014Instituto de Salud Carlos III RD12/0036/0069Instituto de Salud Carlos III RD12/0036/0071Spanish Health Research Program PI12/02321
6 · The paper itself

Abstract

In recent years, several attempts have been made to identify novel prognostic markers in patients with intermediate-risk acute myeloid leukemia (IR-AML), to implement risk-adapted strategies. The non-receptor tyrosine kinases are proteins involved in regulation of cell growth, adhesion, migration and apoptosis. They associate with metastatic dissemination in solid tumors and poor prognosis. However, their role in haematological malignancies has been scarcely studied. We hypothesized that

Indexed as

acute myeloid leukemiaintermediate-riskLYNprognostic factorPTK2PTK2B

Identifiers

PMID30428571
PMCPMC6265715
OpenAlexW2901696845

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.